Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

Phase 3CompletedNCT00219583

Pfizer460 enrolled

Overview

Assessment of efficacy and safety UK-390,957.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

460

Conditions

Ejaculation

Interventions

UK-390,957DRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Premature ejaculation as defined by DSM-IV Exclusion Criteria: * History of erectile dysfunction

Locations (49)

Outcomes

Primary Outcomes

Assessment of efficacy and safety

Secondary Outcomes

Assessment of quality of sexual life

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Bondi Junction, New South Wales, Australia

Pfizer Investigational Site

St Leonards, New South Wales, Australia

Pfizer Investigational Site

Spring Hill, Queensland, Australia

Pfizer Investigational Site

Adelaide, South Australia, Australia

Pfizer Investigational Site

Malvern, Victoria, Australia

Pfizer Investigational Site

Nedlands, Western Australia, Australia

Pfizer Investigational Site

Mistelbach, Austria

Pfizer Investigational Site

Salzburg, Austria

Pfizer Investigational Site

Edmonton, Alberta, Canada

Pfizer Investigational Site

Victoria, British Columbia, Canada

...and 39 more locations